⁃ Phase 1

• Male or female participants ≥18 years of age

• Histologically or cytologically confirmed metastatic and/or surgically unresectable GIST

• Documented progression on imatinib (Phase 1)

• Documented pathogenic mutation in KIT OR any PDGFRA mutation other than exon 18 mutations, determined through local testing

• At least one measurable lesion by mRECIST v1.1 for participants with GIST

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Resolution of any toxicities from prior treatment(s) to ≤ Grade 1 by NCI CTCAE v5.0 criteria, or have resolved to baseline, at the time of first dose of study drug.

• Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions.

⁃ Additional for Phase 1b Exploratory Cohorts

• For Cohort 1, progressed on imatinib only (second line therapy) and refused or are ineligible for other standard of care (SOC) therapies.

• For Cohort 2, progressed on both imatinib and sunitinib (third line therapy) or progressed on imatinib, sunitinib, and an additional agent (i.e., regorafenib or ripretinib) (fourth line therapy) or progressed on imatinib, sunitinib, regorafenib, and ripretininb (fifth line or greater therapy)

• For Cohort 3, treatment naïve (first line therapy) and refused or are ineligible for other standard of care (SOC) therapies.

• For Cohort 4, met the same criteria as Cohort 2 (third line or greater) and have also had prior treatment with investigational agents NB003 or THE-630 or a line of therapy of bezuclastinib plus sunitinib combination.